⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL780237 | 0.82 | — | — | |
| SCHEMBL3821371 | 0.79 | LMNA (0.41) | — | |
| SCHEMBL161337 | 0.77 | — | — | |
| SCHEMBL161336 | 0.77 | — | — | |
| Ribose (Furanose) SCHEMBL4576206 | 0.77 | LMNA (0.42) | — | |
| SCHEMBL7420813 | 0.77 | HDAC6 (0.39) | — | |
| SCHEMBL1857158 | 0.76 | — | — | |
| SCHEMBL4030743 | 0.74 | LMNA (0.38) | — | |
| SCHEMBL1765849 | 0.72 | GDA (0.34) | — | |
| SCHEMBL27627380 | 0.72 | LMNA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 679 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | claimed |
| EP-4460301-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2024-11-13 | — | — | EP | claimed |
| EP-3720493-B1 | COMBINATIONS OF RIPK1- AND IKK-INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES | UNIV KOELN (DE) | 2024-07-24 | — | — | EP | claimed |
| WO-2023131576-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2023-07-13 | — | — | WO | claimed |
| EP-4209213-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2023-07-12 | — | — | EP | claimed |
| EP-2451794-B1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2016-01-27 | — | — | EP | claimed |
| US-9162994-B2 | 1,2,4-thiazoloidin-3-one derivatives and their use in the treatment of cancer | BETAGENON AB (SE) | 2015-10-20 | — | — | US | claimed |
| US-20130196313-A1 | Pharmacogenetic Method for Prediction of the Efficacy of Methotrexate Monotherapy in Recent-Onset Arthritis | ACADEMISCH ZIEKENHUIS H.O.D.N. LUMC (NL) | 2013-08-01 | — | — | US | claimed |
| US-20130143215-A1 | Methods of Predicting Methotrexate Efficacy and Toxicity | PROMETHEUS LABORATORIES INC. (US) | 2013-06-06 | — | — | US | claimed |
| WO-2013076160-A1 | SUSTAINED RELEASE FORMULATIONS USEFUL IN THE TREATMENT OF DISEASES | Université Libre de Bruxelles (BE) | 2013-05-30 | — | — | WO | claimed |
| WO-2006116684-A2 | METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY | PROMETHEUS LABORATORIES, INC. (US) | 2006-11-02 | — | — | WO | claimed |
| EP-1668337-A2 | METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS | Prometheus Laboratories, Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| EP-1495006-A4 | INHIBITORS OF GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE | SCRIPPS RESEARCH INST (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050112627-A1 | Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics | PROMETHEUS LABORATORIES INC. (US) | 2005-05-26 | — | — | US | claimed |
| WO-2005022118-A2 | METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS | PROMETHEUS LABORATORIES, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| EP-1495006-A1 | INHIBITORS OF GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE | The Scripps Research Institute (US) | 2005-01-12 | — | — | EP | claimed |
| US-20040156826-A1 | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2004-08-12 | — | — | US | claimed |
| WO-2004028339-A2 | TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS BASED ON GENE EXPRESSION CHANGES IN CENTRAL NERVOUS SYSTEM TISSUES | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2004-04-08 | — | — | WO | claimed |
| WO-2003087065-A1 | INHIBITORS OF GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030166201-A1 | Selection systems for genetically modified cells | CITY OF HOPE | 2003-09-04 | — | — | US | claimed |